IPSC - Century Therapeutics receives IND clearance for allogeneic cell therapy candidate
- Century Therapeutics ( NASDAQ: IPSC ) will begin a phase 1 study of its allogeneic cell therapy CNTY-101 by the end of the year after receiving Investigational New Drug clearance from the US FDA.
- CNTY-101 is under investigation for relapsed or refractory CD19 positive B-cell malignancies.
- In the ELiPSE-1 study, all patients will receive an initial standard dose of conditioning chemotherapy. Schedule A consists of a single-dose escalation of CNTY-101 and subcutaneous IL-2. Schedule B will evaluate a three-dose schedule per cycle of CNTY-101.
- CNTY-101 is derived from a clonal induced pluripotent stem cell (iPSC) master cell bank that yields homogeneous product.
- Seeking Alpha's Quant Rating views Century ( IPSC ) as a hold with strong grades for profitability and momentum .
For further details see:
Century Therapeutics receives IND clearance for allogeneic cell therapy candidate